SEARCH

Current Edition

agents

ADCs – From Lab to Clinical Development

Antibody-drug conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. Compared to traditional small-molecule approaches, ADCs offer enhanced targeting of …

Continue Reading →
BIO

Upstream Bio, a richly funded startup, reveals its lead drug and research plans

An inflammatory disease drug cast aside by Astellas Pharma has a new owner in Upstream Bio, an emerging biotechnology startup led by industry veteran Samantha …

Continue Reading →
cancer

Regeneron buys control of cancer drug Libtayo from Sanofi

Dive Brief: Regeneron will pay partner Sanofi $900 million to gain global rights to the companies’ cancer immunotherapy Libtayo, announcing Thursday a deal executives said would …

Continue Reading →
Amgen

Mirati matches Amgen with updated data for KRAS-blocking cancer drug

Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive …

Continue Reading →
Biotech

Trial setback casts doubt on a biotech’s respiratory virus drug

Dive Brief: Enanta Pharmaceuticals’ pill to combat respiratory syncytial virus didn’t work in low-risk patients, with the company reporting Wednesday the antiviral did not significantly …

Continue Reading →
Bristol

Key Bristol Myers drug holds up in long-term psoriasis study

Dive Brief: An experimental psoriasis drug developed by Bristol Myers Squibb maintained its effectiveness over more than a year of treatment in a clinical trial …

Continue Reading →
cancer

Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class

Dive Brief: A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form …

Continue Reading →
cancer

Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug

Dive Brief: Taiho Pharmaceutical is buying back rights to an experimental cancer drug aimed at a genetic driver of lung tumors after licensing it to …

Continue Reading →
approvals

With spotlight on FDA, Congress weighs reforms to accelerated drug approvals

Over the past few years, the Food and Drug Administration has come increasingly under scrutiny for its program to grant speedy approvals to drugs that …

Continue Reading →
Alzheimer

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …

Continue Reading →
Aduhelm

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is now …

Continue Reading →
AstraZeneca

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug …

Continue Reading →
diabetes

Lilly’s closely watched diabetes drug scores in obesity trial

Dive Brief: Eli Lilly’s experimental diabetes shot tirzepatide helped obese people who have an underlying medical condition lose more than 15% of their body weight …

Continue Reading →
company

Novartis names longtime analyst as top dealmaker amid organizational shakeup

Dive Brief: Novartis on Tuesday named Ronny Gal, a longtime analyst with advisory firm Bernstein, as its chief strategy and growth officer, the latest move …

Continue Reading →
Amgen

FDA sets back Novartis’ best chance at a COVID-19 drug

Dive Brief: Novartis is reevaluating its commitment to an experimental COVID-19 treatment originally developed by fellow Swiss drug company Molecular Partners after the Food and …

Continue Reading →
COVID-19

Drug price hikes moderate as rebates rise, report finds

Dive Brief: List prices of branded drugs in the U.S. rose by an average of nearly 5% last year, according to a report released Thursday …

Continue Reading →
biotechnology

A promising cancer drug leads Regeneron to reconsider its aversion to M&A

Dive Brief: Regeneron has agreed to purchase a young biotechnology company for access to a drug that the buyer believes will be a valuable component …

Continue Reading →
cancer

Seagen to expand, add jobs with new cancer drug factory

Dive Brief: Seagen, the largest biotechnology company in the Seattle area, has unveiled plans for a manufacturing facility to help provide “greater control and flexibility” …

Continue Reading →
Aduhelm

Biogen pulls European application for Aduhelm in another setback for the Alzheimer’s drug

Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer’s disease drug in Europe, marking the latest setback in the company’s efforts to …

Continue Reading →
cancer

GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on the cusp …

Continue Reading →